2015 Impact Factor of Translational Cancer Research: 1.757

Published: 2016-06-14

Editorial Office, Translational Cancer Research, AME Publishing Company, Guangzhou 510220, China.

It is great to announce that Translational Cancer Research (TCR) gains its 2015 impact factor: 1.757, as per the latest Journal Citation Report released by Thomson Reuters on June 14, 2016. This is the first impact factor that TCR has obtained since its coverage by Science Citation Index Expanded (SCIE), service of Thomson Reuters from October 2015.

Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803) was first launched in June 2012. It is an open-access, peer-reviewed journal published bimonthly both in print and online. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients' quality of life. Published and run by AME Publishing Company, the operation of TCR journal is driven by the leadership and passion of Editor-in-Chief, Prof. Eric Chuang (National Taiwan University); Co-Editor-in- Chief, Prof. Huan Giap (Scripps Proton Therapy Center). They devote their time and bring their decades of experience in scientific research and publications for managing this journal. 

The announcement of the first impact factor is a new mark for TCR, but also beginning of a higher developing stage. Here, we would like to extend our heartfelt gratitude to all our Editorial Team Members, Guest Editors, authors and reviewers for their significant contributions, and we look forward to continuous cooperation with all above mentioned and those who are interested in translational cancer research to bring more exciting contents to readers in the coming future.